2025-07-26 - Analysis Report
Okay, here's an analysis of TG Therapeutics Inc (TGTX) based on the information you've provided, presented in a report format suitable for English.

**Report: TG Therapeutics Inc (TGTX) Analysis**

**1. Performance Overview vs. S&P 500 (VOO)**

*   **Ticker:** TGTX
*   **Company Overview:** TG Therapeutics Inc is a biopharmaceutical company focused on the development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.

*   **Key Performance Metrics:**
    *   TGTX Cumulative Return: 63.31%
    *   VOO Cumulative Return: 99.66%
    *   Performance Spread (TGTX - VOO): -36.35%
    *   Historical Spread Range: Max 401.1, Min -110.5
    *   Current Spread: -31.1
    *   Relative Spread Position: 15.5 (This indicates the current spread is in the lower range of its historical values, suggesting relative underperformance compared to VOO over the analyzed period).

*   **Alpha/Beta Analysis Table:**

| Year       | CAGR    | MDD     | Alpha    | Beta   | Cap(B) |
|------------|---------|---------|----------|--------|--------|
| 2015-2017  | -6.0%   | 56.5%   | -35.0%   | -0.1   | 1.3    |
| 2016-2018  | -8.0%   | 58.6%   | -26.0%   | 0.0    | 0.7    |
| 2017-2019  | 74.0%   | 58.6%   | 44.0%    | 0.0    | 1.8    |
| 2018-2020  | 402.0%  | 58.6%   | 382.0%   | -0.4   | 8.3    |
| 2019-2021  | 125.0%  | 63.5%   | 76.0%    | -0.5   | 3.0    |
| 2020-2022  | -76.0%  | 70.4%   | -78.0%   | -0.6   | 1.9    |
| 2021-2023  | -350.0% | 70.4%   | -368.0%  | -0.8   | 2.7    |
| 2022-2024  | 71.0%   | 73.1%   | 45.0%    | -0.9   | 4.8    |
| 2023-2025  | 70.0%   | 73.1%   | 19.0%    | 0.4    | 5.9    |

*   **Analysis:**
    *   The table reveals significant volatility in TGTX's performance over different periods.
    *   The Alpha values indicate periods of considerable outperformance (e.g., 2018-2020) and underperformance (e.g., 2021-2023) relative to the S&P 500.
    *   The Beta values are generally low, suggesting a weak correlation with the overall market. In some years it is negative beta.
    *   High MDD(Maximum DrawDown) values across all periods point to substantial risk.
    *   CAGR(Compound Annual Growth Rate) also show quite a bit of variability.

**2. Recent Price Action**

*   **Current Price:** 36.90
*   **Last Market Data:**
    *   Price: 36.90
    *   Previous Close: 36.53
    *   Change: 1.01 (A positive change)
*   **Moving Averages:**
    *   5-day MA: 37.16
    *   20-day MA: 37.22
    *   60-day MA: 36.81

*   **Analysis:** The current price is slightly below the 5-day and 20-day moving averages but above the 60-day moving average. This suggests a possible short-term downtrend or consolidation after a recent upward movement. The recent positive change in price indicates some upward momentum.

**3. Technical Indicators and Outlook**

*   **Market Risk Indicator (MRI):** 0.33 (Low Risk)
*   **RSI:** 54.17 (Neutral)
*   **PPO:** -0.31 (Slightly bearish)
*   **Hybrid Signal:** cash_70%_Sell - Suggests selling 70% of holdings due to market conditions and the MRI.
*   **Recent (20-day) Relative Spread Change:** -0.9 (Negative - Short-term decline)
*   **Expected Return:** -253.8% (Significant underperformance vs. S&P 500 over a 2+ year horizon)

*   **Analysis:**
    *   The MRI indicates relatively low market risk, which might seem contradictory given the negative expected return. This discrepancy could be due to company-specific factors outweighing broader market conditions.
    *   The RSI is neutral, indicating neither overbought nor oversold conditions.
    *   The negative PPO suggests the price is slightly below its moving average, hinting at bearish momentum.
    *   The Hybrid Signal's recommendation to sell a significant portion of holdings is a strong bearish signal.
    *   The large negative expected return is a major concern, suggesting significant potential underperformance.
    *   The positive price change of 1.01 indicates a possible short-term rebound, however, it is still against the advice of the hybrid signal.

**4. Recent News & Significant Events**

*   **2025-07-26:** Major business developments, regulatory changes, or market events.
*   **2025-07-25:** Analyst discussions on recent performance and outlook.
*   **2025-07-23:** Notable stock volatility influenced by recent news, earnings reports, or executive actions.
*   **2025-07-22:** Market experts highlight risks and opportunities.

*   **Analysis:** The news snippets indicate that TGTX is subject to significant market attention, with notable volatility and analyst scrutiny. The focus on "risks and opportunities" suggests a mixed outlook and the need for careful monitoring of company announcements.

**5. Recent Earnings Analysis**

| 날짜       | EPS   | 매출        |
|------------|-------|-------------|
| 2025-05-09 | 0.03  | 0.12 B$     |
| 2024-11-07 | 0.03  | 0.08 B$     |
| 2024-08-09 | 0.05  | 0.07 B$     |
| 2024-05-06 | -0.07 | 0.06 B$     |
| 2025-05-09 | -0.07 | 0.06 B$     |

*   **Analysis:**
    *   Earnings per share (EPS) has been volatile, fluctuating between positive and negative values. The most recent data shows positive earnings, which is a positive sign.
    *   Revenue has generally increased over the observed periods, indicating some growth in the company's sales. The EPS of 0.03 and Revenue of 0.12B$ in 2025-05-09 is quite a remarkable result.

**6. Financial Information**

| Quarter    | Revenue | Profit Margin |
|------------|---------|---------------|
| 2025-03-31 | $0.12B  | 87.14%        |
| 2024-12-31 | $0.11B  | 85.77%        |
| 2024-09-30 | $0.08B  | 88.86%        |
| 2024-06-30 | $0.07B  | 88.70%        |
| 2024-03-31 | $0.06B  | 91.43%        |

| Quarter    | Equity  | ROE      |
|------------|---------|----------|
| 2025-03-31 | $0.24B  | 2.13%    |
| 2024-12-31 | $0.22B  | 10.49%   |
| 2024-09-30 | $0.19B  | 2.02%    |
| 2024-06-30 | $0.18B  | 3.87%    |
| 2024-03-31 | $0.16B  | -6.69%   |

*   **Analysis:**
    *   Revenue has shown a positive trend, growing consistently over the quarters.
    *   Profit margins are exceptionally high, indicating strong profitability for each dollar of revenue.
    *   Equity has increased steadily, reflecting the company's growing asset base.
    *   Return on Equity (ROE) has been fluctuating and a bit unstable, but it is trending in a positive direction. The most recent reading is positive, but is low(2.13%).

**7. Overall Conclusion**

Based on the provided data, TG Therapeutics Inc. presents a mixed picture:

*   **Positives:** Recent earnings and revenue growth are encouraging, along with high-profit margins. Recent news is a positive sign.
*   **Negatives:** Historical performance significantly lags the S&P 500, with high volatility and a large negative expected return. The Hybrid Signal suggests caution and selling holdings. The company experienced recent price change, which suggest a short-term rebound, so an action should be taken considering the hybrid signal.
*   **Recommendation:** Given the negative expected return and the bearish Hybrid Signal, investors should exercise significant caution. Monitor upcoming news and developments closely. Consider reducing or eliminating holdings unless there are compelling reasons to remain invested.
